Global Clinical Trials

Clinical Trials Comprehensive Study by Type (Interventional, Observational, Expanded Access), Application (Autoimmune/Inflammation, Pain Management, Oncology, Cardiovascular, Central Nervous System (CNS) Condition, Diabetes, Obesity, Others), End User Industry (Pharmaceuticals Companies, Medical Devices Companies), Component (Clinical Trials Management Software/Systems, Service), Trail Phase (Phase 0, Phase I, Phase II, Phase III, Phase IV) Players and Region - Global Market Outlook to 2030

Clinical Trials Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Clinical Trials Market Overview:
Clinical Trials are a type of research that studies new tests and treatments and evaluates their effects on human health outcomes. These trials are done to examine the effect of drugs or medicinal devices with the aim of evaluating medical, surgical, or behavioral interventions. It studies how safe and helpful new healthcare developments can be for humans. As per the sources, due to the outbreak of COVID-19, there are over 20 vaccines in the phase II and phase III stage of clinical trials. This global pandemic is supplementing the market growth as many researchers are trying to develop new vaccines to cure COVID-19. As of 2020, the clinical trials for drug/biologics were the most registered studies. Over half of the global clinical trials market is currently consumed by the pharmaceutical industry. The growing demand for cost-effective medications is expected to boost the clinical trials market growth throughout the forecast period.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Artificial Intelligence (AI) and Big Data analytics are being used to enhance trial design, patient recruitment, data analysis, and predictive modeling

Market Growth Drivers:
Growing Occurrence and Demand For Cost-effective Medication and Increasing Investment In Research & Development By Healthcare Industries Drive the Market

Challenges:
Shift To Outsourcing And Contract Research Organizations (CROs) and Increasing Use Of Technology in Clinical Trials Processes

Restraints:
Long Waiting Time for Clinical Trails and Stringent Regulations for Patient Enrollment

Opportunities:
Adoption of New Technologies In Clinical Research Methodologies by End Users, High Disease Prevalence In Developing Counties and Rising Government Support In the Clinical Trials Process

Competitive Landscape:

Some of the key players profiled in the report are Charles River Laboratories (United States), Quintiles IMS (United States), Eli Lilly and Company (United States), SGS SA (Switzerland), Paraxel International Corporation (United States), Pfizer Inc. (United States), Novo Nordisk A/S (United States), Clinipace (United States), Laboratory Corporation of America (United States), ICON Plc (Ireland), IQVIA (United States), Pharmaceutical Product Development, LLC(United States), Syneos Health (United States), PRA Health Sciences (United States) and Wuxi AppTec (China). Additionally, following companies can also be profiled that are part of our coverage like Medpace Holdings, Inc. (United States), Siro Clinpharm Pvt. Ltd (India), Parexel International Corp (United States) and Chiltern International Limited (United Kingdom). Considering Market by End User Industry, the sub-segment i.e. Pharmaceuticals Companies will boost the Clinical Trials market. Considering Market by Component, the sub-segment i.e. Clinical Trials Management Software/Systems will boost the Clinical Trials market. Considering Market by Trail Phase, the sub-segment i.e. Phase 0 will boost the Clinical Trials market.

Latest Market Insights:
In October 2019, ICON plc acquired Symphony Clinical Research, a leading provider of at-home patient and site support services. This acquisition enables the ICON to have Symphony’s integrated clinical trial expertise and its strong therapeutic expertise to enhance the ICON’s hybrid trial solutions.

In December 2020, Dr. Reddy's Laboratories Ltd signed a partnership with the Biotechnology Industry Research Assistance Council (BIRAC) for advisory support on clinical trials of the Sputnik V vaccine in India.

The FDA regulates clinical trials in the United States. It reviews trial protocols, monitors participant safety, and assesses the efficacy and safety of drugs, biologics, and medical devices.

What Can be Explored with the Clinical Trials Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Clinical Trials Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Clinical Trials
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Clinical Trials market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Clinical Trials market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Clinical Trials Service Providers, Contract Research Organizations, Venture Capitalists and Private Equity Firms, Government Regulatory and End-User Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Interventional
  • Observational
  • Expanded Access
By Application
  • Autoimmune/Inflammation
  • Pain Management
  • Oncology
  • Cardiovascular
  • Central Nervous System (CNS) Condition
  • Diabetes
  • Obesity
  • Others
By End User Industry
  • Pharmaceuticals Companies
  • Medical Devices Companies

By Component
  • Clinical Trials Management Software/Systems
  • Service

By Trail Phase
  • Phase 0
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Occurrence and Demand For Cost-effective Medication
      • 3.2.2. Increasing Investment In Research & Development By Healthcare Industries Drive the Market
    • 3.3. Market Challenges
      • 3.3.1. Shift To Outsourcing And Contract Research Organizations (CROs)
      • 3.3.2. Increasing Use Of Technology in Clinical Trials Processes
    • 3.4. Market Trends
      • 3.4.1. Artificial Intelligence (AI) and Big Data analytics are being used to enhance trial design, patient recruitment, data analysis, and predictive modeling
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Clinical Trials, by Type, Application, End User Industry, Component, Trail Phase and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Clinical Trials (Value)
      • 5.2.1. Global Clinical Trials by: Type (Value)
        • 5.2.1.1. Interventional
        • 5.2.1.2. Observational
        • 5.2.1.3. Expanded Access
      • 5.2.2. Global Clinical Trials by: Application (Value)
        • 5.2.2.1. Autoimmune/Inflammation
        • 5.2.2.2. Pain Management
        • 5.2.2.3. Oncology
        • 5.2.2.4. Cardiovascular
        • 5.2.2.5. Central Nervous System (CNS) Condition
        • 5.2.2.6. Diabetes
        • 5.2.2.7. Obesity
        • 5.2.2.8. Others
      • 5.2.3. Global Clinical Trials by: End User Industry (Value)
        • 5.2.3.1. Pharmaceuticals Companies
        • 5.2.3.2. Medical Devices Companies
      • 5.2.4. Global Clinical Trials by: Component (Value)
        • 5.2.4.1. Clinical Trials Management Software/Systems
        • 5.2.4.2. Service
      • 5.2.5. Global Clinical Trials by: Trail Phase (Value)
        • 5.2.5.1. Phase 0
        • 5.2.5.2. Phase I
        • 5.2.5.3. Phase II
        • 5.2.5.4. Phase III
        • 5.2.5.5. Phase IV
      • 5.2.6. Global Clinical Trials Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Clinical Trials (Price)
      • 5.3.1. Global Clinical Trials by: Type (Price)
  • 6. Clinical Trials: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Charles River Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Quintiles IMS (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. SGS SA (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Paraxel International Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novo Nordisk A/S (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Clinipace (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Laboratory Corporation of America (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ICON Plc (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. IQVIA (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Pharmaceutical Product Development, LLC(United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Syneos Health (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. PRA Health Sciences (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Wuxi AppTec (China)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Clinical Trials Sale, by Type, Application, End User Industry, Component, Trail Phase and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Clinical Trials (Value)
      • 7.2.1. Global Clinical Trials by: Type (Value)
        • 7.2.1.1. Interventional
        • 7.2.1.2. Observational
        • 7.2.1.3. Expanded Access
      • 7.2.2. Global Clinical Trials by: Application (Value)
        • 7.2.2.1. Autoimmune/Inflammation
        • 7.2.2.2. Pain Management
        • 7.2.2.3. Oncology
        • 7.2.2.4. Cardiovascular
        • 7.2.2.5. Central Nervous System (CNS) Condition
        • 7.2.2.6. Diabetes
        • 7.2.2.7. Obesity
        • 7.2.2.8. Others
      • 7.2.3. Global Clinical Trials by: End User Industry (Value)
        • 7.2.3.1. Pharmaceuticals Companies
        • 7.2.3.2. Medical Devices Companies
      • 7.2.4. Global Clinical Trials by: Component (Value)
        • 7.2.4.1. Clinical Trials Management Software/Systems
        • 7.2.4.2. Service
      • 7.2.5. Global Clinical Trials by: Trail Phase (Value)
        • 7.2.5.1. Phase 0
        • 7.2.5.2. Phase I
        • 7.2.5.3. Phase II
        • 7.2.5.4. Phase III
        • 7.2.5.5. Phase IV
      • 7.2.6. Global Clinical Trials Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Clinical Trials (Price)
      • 7.3.1. Global Clinical Trials by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Clinical Trials: by Type(USD Million)
  • Table 2. Clinical Trials Interventional , by Region USD Million (2018-2023)
  • Table 3. Clinical Trials Observational , by Region USD Million (2018-2023)
  • Table 4. Clinical Trials Expanded Access , by Region USD Million (2018-2023)
  • Table 5. Clinical Trials: by Application(USD Million)
  • Table 6. Clinical Trials Autoimmune/Inflammation , by Region USD Million (2018-2023)
  • Table 7. Clinical Trials Pain Management , by Region USD Million (2018-2023)
  • Table 8. Clinical Trials Oncology , by Region USD Million (2018-2023)
  • Table 9. Clinical Trials Cardiovascular , by Region USD Million (2018-2023)
  • Table 10. Clinical Trials Central Nervous System (CNS) Condition , by Region USD Million (2018-2023)
  • Table 11. Clinical Trials Diabetes , by Region USD Million (2018-2023)
  • Table 12. Clinical Trials Obesity , by Region USD Million (2018-2023)
  • Table 13. Clinical Trials Others , by Region USD Million (2018-2023)
  • Table 14. Clinical Trials: by End User Industry(USD Million)
  • Table 15. Clinical Trials Pharmaceuticals Companies , by Region USD Million (2018-2023)
  • Table 16. Clinical Trials Medical Devices Companies , by Region USD Million (2018-2023)
  • Table 17. Clinical Trials: by Component(USD Million)
  • Table 18. Clinical Trials Clinical Trials Management Software/Systems , by Region USD Million (2018-2023)
  • Table 19. Clinical Trials Service , by Region USD Million (2018-2023)
  • Table 20. Clinical Trials: by Trail Phase(USD Million)
  • Table 21. Clinical Trials Phase 0 , by Region USD Million (2018-2023)
  • Table 22. Clinical Trials Phase I , by Region USD Million (2018-2023)
  • Table 23. Clinical Trials Phase II , by Region USD Million (2018-2023)
  • Table 24. Clinical Trials Phase III , by Region USD Million (2018-2023)
  • Table 25. Clinical Trials Phase IV , by Region USD Million (2018-2023)
  • Table 26. South America Clinical Trials, by Country USD Million (2018-2023)
  • Table 27. South America Clinical Trials, by Type USD Million (2018-2023)
  • Table 28. South America Clinical Trials, by Application USD Million (2018-2023)
  • Table 29. South America Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 30. South America Clinical Trials, by Component USD Million (2018-2023)
  • Table 31. South America Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 32. Brazil Clinical Trials, by Type USD Million (2018-2023)
  • Table 33. Brazil Clinical Trials, by Application USD Million (2018-2023)
  • Table 34. Brazil Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 35. Brazil Clinical Trials, by Component USD Million (2018-2023)
  • Table 36. Brazil Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 37. Argentina Clinical Trials, by Type USD Million (2018-2023)
  • Table 38. Argentina Clinical Trials, by Application USD Million (2018-2023)
  • Table 39. Argentina Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 40. Argentina Clinical Trials, by Component USD Million (2018-2023)
  • Table 41. Argentina Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 42. Rest of South America Clinical Trials, by Type USD Million (2018-2023)
  • Table 43. Rest of South America Clinical Trials, by Application USD Million (2018-2023)
  • Table 44. Rest of South America Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 45. Rest of South America Clinical Trials, by Component USD Million (2018-2023)
  • Table 46. Rest of South America Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 47. Asia Pacific Clinical Trials, by Country USD Million (2018-2023)
  • Table 48. Asia Pacific Clinical Trials, by Type USD Million (2018-2023)
  • Table 49. Asia Pacific Clinical Trials, by Application USD Million (2018-2023)
  • Table 50. Asia Pacific Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 51. Asia Pacific Clinical Trials, by Component USD Million (2018-2023)
  • Table 52. Asia Pacific Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 53. China Clinical Trials, by Type USD Million (2018-2023)
  • Table 54. China Clinical Trials, by Application USD Million (2018-2023)
  • Table 55. China Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 56. China Clinical Trials, by Component USD Million (2018-2023)
  • Table 57. China Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 58. Japan Clinical Trials, by Type USD Million (2018-2023)
  • Table 59. Japan Clinical Trials, by Application USD Million (2018-2023)
  • Table 60. Japan Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 61. Japan Clinical Trials, by Component USD Million (2018-2023)
  • Table 62. Japan Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 63. India Clinical Trials, by Type USD Million (2018-2023)
  • Table 64. India Clinical Trials, by Application USD Million (2018-2023)
  • Table 65. India Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 66. India Clinical Trials, by Component USD Million (2018-2023)
  • Table 67. India Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 68. South Korea Clinical Trials, by Type USD Million (2018-2023)
  • Table 69. South Korea Clinical Trials, by Application USD Million (2018-2023)
  • Table 70. South Korea Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 71. South Korea Clinical Trials, by Component USD Million (2018-2023)
  • Table 72. South Korea Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 73. Taiwan Clinical Trials, by Type USD Million (2018-2023)
  • Table 74. Taiwan Clinical Trials, by Application USD Million (2018-2023)
  • Table 75. Taiwan Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 76. Taiwan Clinical Trials, by Component USD Million (2018-2023)
  • Table 77. Taiwan Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 78. Australia Clinical Trials, by Type USD Million (2018-2023)
  • Table 79. Australia Clinical Trials, by Application USD Million (2018-2023)
  • Table 80. Australia Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 81. Australia Clinical Trials, by Component USD Million (2018-2023)
  • Table 82. Australia Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Clinical Trials, by Type USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Clinical Trials, by Application USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Clinical Trials, by Component USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 88. Europe Clinical Trials, by Country USD Million (2018-2023)
  • Table 89. Europe Clinical Trials, by Type USD Million (2018-2023)
  • Table 90. Europe Clinical Trials, by Application USD Million (2018-2023)
  • Table 91. Europe Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 92. Europe Clinical Trials, by Component USD Million (2018-2023)
  • Table 93. Europe Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 94. Germany Clinical Trials, by Type USD Million (2018-2023)
  • Table 95. Germany Clinical Trials, by Application USD Million (2018-2023)
  • Table 96. Germany Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 97. Germany Clinical Trials, by Component USD Million (2018-2023)
  • Table 98. Germany Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 99. France Clinical Trials, by Type USD Million (2018-2023)
  • Table 100. France Clinical Trials, by Application USD Million (2018-2023)
  • Table 101. France Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 102. France Clinical Trials, by Component USD Million (2018-2023)
  • Table 103. France Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 104. Italy Clinical Trials, by Type USD Million (2018-2023)
  • Table 105. Italy Clinical Trials, by Application USD Million (2018-2023)
  • Table 106. Italy Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 107. Italy Clinical Trials, by Component USD Million (2018-2023)
  • Table 108. Italy Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 109. United Kingdom Clinical Trials, by Type USD Million (2018-2023)
  • Table 110. United Kingdom Clinical Trials, by Application USD Million (2018-2023)
  • Table 111. United Kingdom Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 112. United Kingdom Clinical Trials, by Component USD Million (2018-2023)
  • Table 113. United Kingdom Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 114. Netherlands Clinical Trials, by Type USD Million (2018-2023)
  • Table 115. Netherlands Clinical Trials, by Application USD Million (2018-2023)
  • Table 116. Netherlands Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 117. Netherlands Clinical Trials, by Component USD Million (2018-2023)
  • Table 118. Netherlands Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 119. Rest of Europe Clinical Trials, by Type USD Million (2018-2023)
  • Table 120. Rest of Europe Clinical Trials, by Application USD Million (2018-2023)
  • Table 121. Rest of Europe Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 122. Rest of Europe Clinical Trials, by Component USD Million (2018-2023)
  • Table 123. Rest of Europe Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 124. MEA Clinical Trials, by Country USD Million (2018-2023)
  • Table 125. MEA Clinical Trials, by Type USD Million (2018-2023)
  • Table 126. MEA Clinical Trials, by Application USD Million (2018-2023)
  • Table 127. MEA Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 128. MEA Clinical Trials, by Component USD Million (2018-2023)
  • Table 129. MEA Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 130. Middle East Clinical Trials, by Type USD Million (2018-2023)
  • Table 131. Middle East Clinical Trials, by Application USD Million (2018-2023)
  • Table 132. Middle East Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 133. Middle East Clinical Trials, by Component USD Million (2018-2023)
  • Table 134. Middle East Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 135. Africa Clinical Trials, by Type USD Million (2018-2023)
  • Table 136. Africa Clinical Trials, by Application USD Million (2018-2023)
  • Table 137. Africa Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 138. Africa Clinical Trials, by Component USD Million (2018-2023)
  • Table 139. Africa Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 140. North America Clinical Trials, by Country USD Million (2018-2023)
  • Table 141. North America Clinical Trials, by Type USD Million (2018-2023)
  • Table 142. North America Clinical Trials, by Application USD Million (2018-2023)
  • Table 143. North America Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 144. North America Clinical Trials, by Component USD Million (2018-2023)
  • Table 145. North America Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 146. United States Clinical Trials, by Type USD Million (2018-2023)
  • Table 147. United States Clinical Trials, by Application USD Million (2018-2023)
  • Table 148. United States Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 149. United States Clinical Trials, by Component USD Million (2018-2023)
  • Table 150. United States Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 151. Canada Clinical Trials, by Type USD Million (2018-2023)
  • Table 152. Canada Clinical Trials, by Application USD Million (2018-2023)
  • Table 153. Canada Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 154. Canada Clinical Trials, by Component USD Million (2018-2023)
  • Table 155. Canada Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 156. Mexico Clinical Trials, by Type USD Million (2018-2023)
  • Table 157. Mexico Clinical Trials, by Application USD Million (2018-2023)
  • Table 158. Mexico Clinical Trials, by End User Industry USD Million (2018-2023)
  • Table 159. Mexico Clinical Trials, by Component USD Million (2018-2023)
  • Table 160. Mexico Clinical Trials, by Trail Phase USD Million (2018-2023)
  • Table 161. Clinical Trials: by Type(USD/Units)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Clinical Trials: by Type(USD Million)
  • Table 178. Clinical Trials Interventional , by Region USD Million (2025-2030)
  • Table 179. Clinical Trials Observational , by Region USD Million (2025-2030)
  • Table 180. Clinical Trials Expanded Access , by Region USD Million (2025-2030)
  • Table 181. Clinical Trials: by Application(USD Million)
  • Table 182. Clinical Trials Autoimmune/Inflammation , by Region USD Million (2025-2030)
  • Table 183. Clinical Trials Pain Management , by Region USD Million (2025-2030)
  • Table 184. Clinical Trials Oncology , by Region USD Million (2025-2030)
  • Table 185. Clinical Trials Cardiovascular , by Region USD Million (2025-2030)
  • Table 186. Clinical Trials Central Nervous System (CNS) Condition , by Region USD Million (2025-2030)
  • Table 187. Clinical Trials Diabetes , by Region USD Million (2025-2030)
  • Table 188. Clinical Trials Obesity , by Region USD Million (2025-2030)
  • Table 189. Clinical Trials Others , by Region USD Million (2025-2030)
  • Table 190. Clinical Trials: by End User Industry(USD Million)
  • Table 191. Clinical Trials Pharmaceuticals Companies , by Region USD Million (2025-2030)
  • Table 192. Clinical Trials Medical Devices Companies , by Region USD Million (2025-2030)
  • Table 193. Clinical Trials: by Component(USD Million)
  • Table 194. Clinical Trials Clinical Trials Management Software/Systems , by Region USD Million (2025-2030)
  • Table 195. Clinical Trials Service , by Region USD Million (2025-2030)
  • Table 196. Clinical Trials: by Trail Phase(USD Million)
  • Table 197. Clinical Trials Phase 0 , by Region USD Million (2025-2030)
  • Table 198. Clinical Trials Phase I , by Region USD Million (2025-2030)
  • Table 199. Clinical Trials Phase II , by Region USD Million (2025-2030)
  • Table 200. Clinical Trials Phase III , by Region USD Million (2025-2030)
  • Table 201. Clinical Trials Phase IV , by Region USD Million (2025-2030)
  • Table 202. South America Clinical Trials, by Country USD Million (2025-2030)
  • Table 203. South America Clinical Trials, by Type USD Million (2025-2030)
  • Table 204. South America Clinical Trials, by Application USD Million (2025-2030)
  • Table 205. South America Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 206. South America Clinical Trials, by Component USD Million (2025-2030)
  • Table 207. South America Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 208. Brazil Clinical Trials, by Type USD Million (2025-2030)
  • Table 209. Brazil Clinical Trials, by Application USD Million (2025-2030)
  • Table 210. Brazil Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 211. Brazil Clinical Trials, by Component USD Million (2025-2030)
  • Table 212. Brazil Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 213. Argentina Clinical Trials, by Type USD Million (2025-2030)
  • Table 214. Argentina Clinical Trials, by Application USD Million (2025-2030)
  • Table 215. Argentina Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 216. Argentina Clinical Trials, by Component USD Million (2025-2030)
  • Table 217. Argentina Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 218. Rest of South America Clinical Trials, by Type USD Million (2025-2030)
  • Table 219. Rest of South America Clinical Trials, by Application USD Million (2025-2030)
  • Table 220. Rest of South America Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 221. Rest of South America Clinical Trials, by Component USD Million (2025-2030)
  • Table 222. Rest of South America Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 223. Asia Pacific Clinical Trials, by Country USD Million (2025-2030)
  • Table 224. Asia Pacific Clinical Trials, by Type USD Million (2025-2030)
  • Table 225. Asia Pacific Clinical Trials, by Application USD Million (2025-2030)
  • Table 226. Asia Pacific Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 227. Asia Pacific Clinical Trials, by Component USD Million (2025-2030)
  • Table 228. Asia Pacific Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 229. China Clinical Trials, by Type USD Million (2025-2030)
  • Table 230. China Clinical Trials, by Application USD Million (2025-2030)
  • Table 231. China Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 232. China Clinical Trials, by Component USD Million (2025-2030)
  • Table 233. China Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 234. Japan Clinical Trials, by Type USD Million (2025-2030)
  • Table 235. Japan Clinical Trials, by Application USD Million (2025-2030)
  • Table 236. Japan Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 237. Japan Clinical Trials, by Component USD Million (2025-2030)
  • Table 238. Japan Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 239. India Clinical Trials, by Type USD Million (2025-2030)
  • Table 240. India Clinical Trials, by Application USD Million (2025-2030)
  • Table 241. India Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 242. India Clinical Trials, by Component USD Million (2025-2030)
  • Table 243. India Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 244. South Korea Clinical Trials, by Type USD Million (2025-2030)
  • Table 245. South Korea Clinical Trials, by Application USD Million (2025-2030)
  • Table 246. South Korea Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 247. South Korea Clinical Trials, by Component USD Million (2025-2030)
  • Table 248. South Korea Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 249. Taiwan Clinical Trials, by Type USD Million (2025-2030)
  • Table 250. Taiwan Clinical Trials, by Application USD Million (2025-2030)
  • Table 251. Taiwan Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 252. Taiwan Clinical Trials, by Component USD Million (2025-2030)
  • Table 253. Taiwan Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 254. Australia Clinical Trials, by Type USD Million (2025-2030)
  • Table 255. Australia Clinical Trials, by Application USD Million (2025-2030)
  • Table 256. Australia Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 257. Australia Clinical Trials, by Component USD Million (2025-2030)
  • Table 258. Australia Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 259. Rest of Asia-Pacific Clinical Trials, by Type USD Million (2025-2030)
  • Table 260. Rest of Asia-Pacific Clinical Trials, by Application USD Million (2025-2030)
  • Table 261. Rest of Asia-Pacific Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 262. Rest of Asia-Pacific Clinical Trials, by Component USD Million (2025-2030)
  • Table 263. Rest of Asia-Pacific Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 264. Europe Clinical Trials, by Country USD Million (2025-2030)
  • Table 265. Europe Clinical Trials, by Type USD Million (2025-2030)
  • Table 266. Europe Clinical Trials, by Application USD Million (2025-2030)
  • Table 267. Europe Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 268. Europe Clinical Trials, by Component USD Million (2025-2030)
  • Table 269. Europe Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 270. Germany Clinical Trials, by Type USD Million (2025-2030)
  • Table 271. Germany Clinical Trials, by Application USD Million (2025-2030)
  • Table 272. Germany Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 273. Germany Clinical Trials, by Component USD Million (2025-2030)
  • Table 274. Germany Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 275. France Clinical Trials, by Type USD Million (2025-2030)
  • Table 276. France Clinical Trials, by Application USD Million (2025-2030)
  • Table 277. France Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 278. France Clinical Trials, by Component USD Million (2025-2030)
  • Table 279. France Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 280. Italy Clinical Trials, by Type USD Million (2025-2030)
  • Table 281. Italy Clinical Trials, by Application USD Million (2025-2030)
  • Table 282. Italy Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 283. Italy Clinical Trials, by Component USD Million (2025-2030)
  • Table 284. Italy Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 285. United Kingdom Clinical Trials, by Type USD Million (2025-2030)
  • Table 286. United Kingdom Clinical Trials, by Application USD Million (2025-2030)
  • Table 287. United Kingdom Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 288. United Kingdom Clinical Trials, by Component USD Million (2025-2030)
  • Table 289. United Kingdom Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 290. Netherlands Clinical Trials, by Type USD Million (2025-2030)
  • Table 291. Netherlands Clinical Trials, by Application USD Million (2025-2030)
  • Table 292. Netherlands Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 293. Netherlands Clinical Trials, by Component USD Million (2025-2030)
  • Table 294. Netherlands Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 295. Rest of Europe Clinical Trials, by Type USD Million (2025-2030)
  • Table 296. Rest of Europe Clinical Trials, by Application USD Million (2025-2030)
  • Table 297. Rest of Europe Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 298. Rest of Europe Clinical Trials, by Component USD Million (2025-2030)
  • Table 299. Rest of Europe Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 300. MEA Clinical Trials, by Country USD Million (2025-2030)
  • Table 301. MEA Clinical Trials, by Type USD Million (2025-2030)
  • Table 302. MEA Clinical Trials, by Application USD Million (2025-2030)
  • Table 303. MEA Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 304. MEA Clinical Trials, by Component USD Million (2025-2030)
  • Table 305. MEA Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 306. Middle East Clinical Trials, by Type USD Million (2025-2030)
  • Table 307. Middle East Clinical Trials, by Application USD Million (2025-2030)
  • Table 308. Middle East Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 309. Middle East Clinical Trials, by Component USD Million (2025-2030)
  • Table 310. Middle East Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 311. Africa Clinical Trials, by Type USD Million (2025-2030)
  • Table 312. Africa Clinical Trials, by Application USD Million (2025-2030)
  • Table 313. Africa Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 314. Africa Clinical Trials, by Component USD Million (2025-2030)
  • Table 315. Africa Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 316. North America Clinical Trials, by Country USD Million (2025-2030)
  • Table 317. North America Clinical Trials, by Type USD Million (2025-2030)
  • Table 318. North America Clinical Trials, by Application USD Million (2025-2030)
  • Table 319. North America Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 320. North America Clinical Trials, by Component USD Million (2025-2030)
  • Table 321. North America Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 322. United States Clinical Trials, by Type USD Million (2025-2030)
  • Table 323. United States Clinical Trials, by Application USD Million (2025-2030)
  • Table 324. United States Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 325. United States Clinical Trials, by Component USD Million (2025-2030)
  • Table 326. United States Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 327. Canada Clinical Trials, by Type USD Million (2025-2030)
  • Table 328. Canada Clinical Trials, by Application USD Million (2025-2030)
  • Table 329. Canada Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 330. Canada Clinical Trials, by Component USD Million (2025-2030)
  • Table 331. Canada Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 332. Mexico Clinical Trials, by Type USD Million (2025-2030)
  • Table 333. Mexico Clinical Trials, by Application USD Million (2025-2030)
  • Table 334. Mexico Clinical Trials, by End User Industry USD Million (2025-2030)
  • Table 335. Mexico Clinical Trials, by Component USD Million (2025-2030)
  • Table 336. Mexico Clinical Trials, by Trail Phase USD Million (2025-2030)
  • Table 337. Clinical Trials: by Type(USD/Units)
  • Table 338. Research Programs/Design for This Report
  • Table 339. Key Data Information from Secondary Sources
  • Table 340. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Clinical Trials: by Type USD Million (2018-2023)
  • Figure 5. Global Clinical Trials: by Application USD Million (2018-2023)
  • Figure 6. Global Clinical Trials: by End User Industry USD Million (2018-2023)
  • Figure 7. Global Clinical Trials: by Component USD Million (2018-2023)
  • Figure 8. Global Clinical Trials: by Trail Phase USD Million (2018-2023)
  • Figure 9. South America Clinical Trials Share (%), by Country
  • Figure 10. Asia Pacific Clinical Trials Share (%), by Country
  • Figure 11. Europe Clinical Trials Share (%), by Country
  • Figure 12. MEA Clinical Trials Share (%), by Country
  • Figure 13. North America Clinical Trials Share (%), by Country
  • Figure 14. Global Clinical Trials: by Type USD/Units (2018-2023)
  • Figure 15. Global Clinical Trials share by Players 2023 (%)
  • Figure 16. Global Clinical Trials share by Players (Top 3) 2023(%)
  • Figure 17. Global Clinical Trials share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. Charles River Laboratories (United States) Revenue: by Geography 2023
  • Figure 21. Quintiles IMS (United States) Revenue, Net Income and Gross profit
  • Figure 22. Quintiles IMS (United States) Revenue: by Geography 2023
  • Figure 23. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 25. SGS SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. SGS SA (Switzerland) Revenue: by Geography 2023
  • Figure 27. Paraxel International Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Paraxel International Corporation (United States) Revenue: by Geography 2023
  • Figure 29. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Novo Nordisk A/S (United States) Revenue, Net Income and Gross profit
  • Figure 32. Novo Nordisk A/S (United States) Revenue: by Geography 2023
  • Figure 33. Clinipace (United States) Revenue, Net Income and Gross profit
  • Figure 34. Clinipace (United States) Revenue: by Geography 2023
  • Figure 35. Laboratory Corporation of America (United States) Revenue, Net Income and Gross profit
  • Figure 36. Laboratory Corporation of America (United States) Revenue: by Geography 2023
  • Figure 37. ICON Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. ICON Plc (Ireland) Revenue: by Geography 2023
  • Figure 39. IQVIA (United States) Revenue, Net Income and Gross profit
  • Figure 40. IQVIA (United States) Revenue: by Geography 2023
  • Figure 41. Pharmaceutical Product Development, LLC(United States) Revenue, Net Income and Gross profit
  • Figure 42. Pharmaceutical Product Development, LLC(United States) Revenue: by Geography 2023
  • Figure 43. Syneos Health (United States) Revenue, Net Income and Gross profit
  • Figure 44. Syneos Health (United States) Revenue: by Geography 2023
  • Figure 45. PRA Health Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 46. PRA Health Sciences (United States) Revenue: by Geography 2023
  • Figure 47. Wuxi AppTec (China) Revenue, Net Income and Gross profit
  • Figure 48. Wuxi AppTec (China) Revenue: by Geography 2023
  • Figure 49. Global Clinical Trials: by Type USD Million (2025-2030)
  • Figure 50. Global Clinical Trials: by Application USD Million (2025-2030)
  • Figure 51. Global Clinical Trials: by End User Industry USD Million (2025-2030)
  • Figure 52. Global Clinical Trials: by Component USD Million (2025-2030)
  • Figure 53. Global Clinical Trials: by Trail Phase USD Million (2025-2030)
  • Figure 54. South America Clinical Trials Share (%), by Country
  • Figure 55. Asia Pacific Clinical Trials Share (%), by Country
  • Figure 56. Europe Clinical Trials Share (%), by Country
  • Figure 57. MEA Clinical Trials Share (%), by Country
  • Figure 58. North America Clinical Trials Share (%), by Country
  • Figure 59. Global Clinical Trials: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Charles River Laboratories (United States)
  • Quintiles IMS (United States)
  • Eli Lilly and Company (United States)
  • SGS SA (Switzerland)
  • Paraxel International Corporation (United States)
  • Pfizer Inc. (United States)
  • Novo Nordisk A/S (United States)
  • Clinipace (United States)
  • Laboratory Corporation of America (United States)
  • ICON Plc (Ireland)
  • IQVIA (United States)
  • Pharmaceutical Product Development, LLC(United States)
  • Syneos Health (United States)
  • PRA Health Sciences (United States)
  • Wuxi AppTec (China)
Additional players considered in the study are as follows:
Medpace Holdings, Inc. (United States) , Siro Clinpharm Pvt. Ltd (India) , Parexel International Corp (United States) , Chiltern International Limited (United Kingdom)
Select User Access Type

Key Highlights of Report


Mar 2024 237 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Clinical Trials Quantitative research analysis
Global Clinical Trials Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Clinical Trials market are Charles River Laboratories (United States), Quintiles IMS (United States), Eli Lilly and Company (United States), SGS SA (Switzerland), Paraxel International Corporation (United States), Pfizer Inc. (United States), Novo Nordisk A/S (United States), Clinipace (United States), Laboratory Corporation of America (United States), ICON Plc (Ireland), IQVIA (United States), Pharmaceutical Product Development, LLC(United States), Syneos Health (United States), PRA Health Sciences (United States) and Wuxi AppTec (China), to name a few.
"Artificial Intelligence (AI) and Big Data analytics are being used to enhance trial design, patient recruitment, data analysis, and predictive modeling" is seen as one of major influencing trends for Clinical Trials Market during projected period 2023-2030.
Interventional segment in Global market to hold robust market share owing to "Growing Occurrence and Demand For Cost-effective Medication ".

Know More About Global Clinical Trials Report?

Have a Query? Click Here

Other Related Reports

Spine Biologics Comprehensive Study by Type (Bone Graft Substitutes (Synthetic Bone Grafts, Demineralized Bone Matrix (DBM), Bone Morphogenetic Proteins (BMP)), Bone Allografts (Machined Bone Allogra...
$ 3750
Skilled Nursing Care Services Comprehensive Study by Type (Home Care, Residential Care, Acute Care), Application (Old Age People, Children), Connectivity (Connected To Hospital, Connected To Assisted...
$ 3650
Blood Bags Comprehensive Study by Type (Single Collection, Double Collection, Triple Collection, Quadruple Collection, Others.), Capacity Type (0 ml – 100 ml, 100 ml – 250 ml, 250 ml -450 ml, 450 ml ...
$ 3650
Breast Lesion Localization Methods Comprehensive Study by Type (Wire, Radioisotope, Electromagnetic, Magnetic, Other), Application (Women, Men), End-Users (Diagnostic Centers, Hospitals, Ambulatory S...
$ 3350
Microbial Identification Service Comprehensive Study by Type (Instruments {Automated Microbial Identification Systems,.Mass Spectrometers, PCR, Microarrays, High-power Microscopes, Polystainers, Flow...
$ 3750
Ultrasonic Toothbrush Comprehensive Study by Type (Single Frequency, Dual Frequency), Application (Therapeutic Medical Devices, Household, Others), Components (Circuit, Motor, Switch, Cam and gears, ...
$ 3450